Goodwin represented Centerview Partners in connection with Galenica Group (SIX:GALN) and Relypsa, Inc.’s (NASDAQ:RLYP) definitive agreement under which Galenica will acquire Relypsa, a biopharmaceutical company focused on the commercialization of its lead asset Veltassa®, approved by the FDA for the treatment of hyperkalemia in October 2015. Under the terms of the merger agreement, Galenica will pay $32 per share in cash, or a total of approximately $1.53 billion.
Centerview Partners acted as co-financial advisor to Relypsa along with BofA Merrill Lynch.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The company's first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science.
Galenica is a diversified group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities.
To learn more about the transaction, please view the joint press release.